Salivary and plasma proteome investigations in individuals with type 2 diabetes mellitus, dyslipidemia and chronic periodontal disease

• Grant number: 15/08678-1
• Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
• Start date: October 05, 2015
• End date: October 04, 2016
• Field of knowledge: Health Sciences - Dentistry - Periodontology
• Principal Investigator: Raquel Mantuaneli Scarel Caminaga
• Grantee: Sâmia Cruz Tfaile Corbi
• Supervisor: Walter Luiz Siqueira
• Host Institution: Faculdade de Odontologia (FOAr). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Institution abroad: Western University , Canada
• Associated to the scholarship: 14/16148-0 - Transcriptome and salivary and plasma proteome investigations in individuals with type 2 diabetes mellitus, dyslipidemia and chronic periodontal disease, BP.PD

Abstract

The aim of this study is to investigate the salivary and plasma proteome related to individuals affected by type 2 Diabetes Mellitus (DM2, metabolically compensated/decompensated), Dyslipidemia and Chronic Periodontal Disease (DP). The development of this study proposes to complement the recently completed PhD study from the requestor (FAPESP 2009/16233-9 and 2010/10882-2) in which five groups of patients were examined (30 patients each): Group 1 (n= 30) - Individuals with DM2, metabolically decompensated (HbA1ce8.0%) with dyslipidemia and PD; Group 2 (n=30) - Individuals with DM2, metabolically compensated (HbA1c<8.0%) with dyslipidemia and PD; Group 3 (n=30) - Individuals without DM2, with dyslipidemia and with PD; Group 4 (n=30) - Individuals without DM2, without dyslipidemia and with DP; Group 5 (n=30) - Individuals without DM2, without dyslipidemia and without PD. In this study it will be investigated the salivary and plasma proteome for identification, characterization and quantification of more/less abundant proteins in saliva and plasma. The SDS-PAGE gels will be prepared in polyacrylamide gradient between 4 and 20% and it will also be made the native PAGE gels for separation and quantification of proteins. Then, it will be used the Reverse Phase Liquid Chromatography and Liquid Chromatography Tandem Mass Spectrometry. After that, it will be selected a protein with greater abundance and another with lower abundance in every Group 1, Group 2, Group 3, Group 4 in comparison with Group 5 (considered to be the control group) for validation by ELISA or Western blotting. It is important to undertake this present study, because the proteins differentially expressed in each condition, after validated, may be investigated as a new therapeutic target, and they are useful for the diagnosis and monitoring of patients affected by these diseases. Furthermore, it is also expected to contribute to the elucidation of the molecular mechanisms involved in these diseases. (AU)